: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002,298(5595):1025–1029.PubMedCrossRef IWR-1 26. Birchler T, Seibl R, Buchner K, Loeliger S, Seger R, Hossle JP, Aguzzi A, Lauener RP: Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 2001,31(11):3131–3137.PubMedCrossRef 27. Jenssen H, Hancock RE: Therapeutic potential

of HDPs as immunomodulatory agents. Methods Mol Biol 2010, 618:329–347.PubMedCrossRef 28. Fisher JW: Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003,228(1):1–14. 29. Tavares PM, Thevissen K, Cammue BP, Francois IE, Barreto-Bergter E, Taborda CP, Marques AF, Rodrigues ML, Nimrichter L: In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis. Antimicrob Agents Chemother 2008,52(12):4522–4525.PubMedCrossRef 30. Cho Y, Turner JS, Dinh NN, Lehrer RI: Activity of protegrins against yeast-phase Candida albicans . Infect Immun 1998,66(6):2486–2493.PubMed 31. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH: Combination antifungal therapy. Antimicrob

Agents Chemother 2004,48(3):693–715.PubMedCrossRef 32. Matsumoto M, Ishida K, Konagai A, Maebashi K, Asaoka T: Strong antifungal activity of SS750, a new triazole derivative, is based on its selective

binding affinity to cytochrome P450 of fungi. Antimicrob Screening Library Agents Chemother 2002,46(2):308–314.PubMedCrossRef 33. Andes D, BGB324 in vitro Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J: In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008,52(2):539–550.PubMedCrossRef 34. Hamad M, Abu-Elteen KH, Ghaleb M: Estrogen-dependent induction of persistent vaginal candidosis in naive mice. Mycoses 2004,47(7):304–309.PubMedCrossRef 35. Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ: Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical Rho studies. Nucl Med Biol 2008,35(4):401–411.PubMedCrossRef Authors’ contributions DR carry out in vitro, in vivo studies and measurement of cytokines, participated in biodistribution experiments, blood analysis, experimental design and helped to write the manuscript. JEM participated in the in vivo, in vitro studies and measurement of cytokines. RB participated in in vivo and in vitro studies. AM synthetised the HYNIC-gomesin. BF was responsible for the biodistribution experiments. PB carries out the blood analysis. DDC was in charge of the statistical analysis. CPT and SD conceived of the study and manuscript preparation. All authors read and approved the final manuscript.